食管鳞癌组织ERCC1及SLC7A11的表达水平对新辅助化疗疗效的影响

doi:10.3969/j.issn.1006-6233.2021.06.018

Abstract
Figure/Table
References
Related Citation (8)

Download: PDF (1519 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To Observe the changes of ERCC1 and SLC7A11 expression in esophageal cancer tissue, and to explore the role of ERCC1 and SLC7A11 in esophageal cancer chemotherapy. Methods: The expression levels of ERCC1 and SLC7A11 in 92 cases of esophageal cancer tissue (experimental group) and 36 cases of normal esophageal mucosa tissue (control group) were detected by SP immunohistochemical method, and the relationship between the relative transcript levels and clinicopathological characteristics of patients with esophageal cancer was analyzed. Results: The positive rates of ERCC1 and SLC7A11 expression in esophageal cancer group were higher than those in control group (P<0.01). The high expression of ERCC1 was correlated with the clinical stages, differentiation degrees and lymph node metastasis of esophageal cancer (P<0.05), but not with gender and age (P>0.05).The high expression of SLC7A11 was correlated with the clinical stages, lymph node metastasis, and differentiation degrees of esophageal cancer (P<0.05), but not with gender and age (P>0.05).Pearson correlation analysis showed that ERCC1 expression level was positively correlated with SLC7A11 expression level.Kaplan-Meier analysis showed that the recurrence rate of esophageal cancer patients with ERCC1 (+)/SLC7A11 (+) high expression was also higher than that of patients with negative ERCC1/ SLC7A11 expression at 3 years after treatment. The difference was statistically significant (P<0.05). The overall survival rate at 3 years was lower than that of patients with negative expression (P < 0.05).Among 81 patients receiving neoadjuvant chemotherapy, there were 59 patients in the sensitive group and 22 patients in the drug resistant group. The positive expression rate of ERCC1 was significantly different between the two groups (P<0.01). The positive expression rate of SLC7A11 was significantly different between the two groups (P<0.05). Conclusion: The expression levels of ERCC1 and SLC7A1,to some extent, are of a certain guiding effect on preoperative neoadjuvant chemotherapy in patients with esophageal cancer, and the efficacy of neoadjuvant chemotherapy in patients with ERCC1 (+)/SLC7A11 (+) high expression is poor.

Key words： Esophageal cancer ERCC1 SLC7A11 Neoadjuvant chemotherapy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2021.06.018 OR http://www.hbyxzzs.cn/EN/Y2021/V27/I6/963

[1] Watanabe M, Otake R, Kozuki R, et al. Recent progress in multidisciplinary treatment for patients with esophageal cancer[J].Surg Today,2020,50(1):12~20.
[2] Fang W. Interpretation of 2017 national comprehensive cancer network (NCCN) guidelines for the diagnosis and treatment of esophageal squamous cell carcinoma through the new TNM staging of esophageal carcinoma (eighth edition) by the Union for international cancer control (UICC) and the American Cancer Commission (AJCC)[J].Zhonghua Wei Chang Wai Ke Za Zhi,2017,20(10):1122~1126.
[3] 朱厚鑫.术前新辅助化疗对局部进展期胃癌近期与远期预后的影响[D].青岛大学,2019.
[4] Duan M, Ulibarri J, Liu KJ, et al. Role of nucleotide excision repair in cisplatin resistance[J].Int Mol Sci,2020, 21(23):9248~9361.
[5] Lin W, Wang C, Liu G, et al.SLC7A11/xCT in cancer: biological functions and therapeutic implications[J].Am Cancer Res,2020,10(10):3106~312.
[6] Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5- fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907)[J].Ann Surg Oncol,2012,19(1):68~74.
[7] 胡倩倩,王振辉,牛超,等.铂类抗肿瘤药物耐药机制研究进展[J].药学进展,2017,41(10):769~774.
[8] 黄玉亮,朱波.切除修复交叉互补基因1与肿瘤的关系研究进展[J].癌症进展,2019,17(4):376~379.
[9] Ozcan MF, Dizdar O, Dincer N, et al. Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy[J].Urol Oncol,2013, 31(8):1709.
[10] 潘婷婷,赵达,唐君霞,戴滋赢,周永宁,陈永林,关泉林.Ki-67、ERCC1的表达对胃癌新辅助化疗病理学缓解的预测价值[J].中国肿瘤,2019,28(7):543~548.
[11] Yin F, Yi S, Wei L, et al. Microarray-based identification of genes associated with prognosis and drug resistance in ovarian cancer[J].Cell Biochem,2019, 120(4):6057~6070.
[12] Horibe S, Kawauchi S, Tanahashi T, et al. CD44v-dependent upregulation of xCT is involved in the acquisition of cisplatin-resistance in human lung cancer A549 cells[J].BiochemBiophys Res Commun,2018, 507(1):426~432.